MDG Boston: Combination Products for Drug Delivery, Oct 30, 2019

Join CBSET at the MDG Boston forum Combination Products for Drug Delivery, October 3o, 2019, at Regis College, Fine Arts Center, 235 Wellesley St, Weston, Massachusetts 02493.

Combination products are defined as a product comprising a medical device and/or a drug and/or a biologic and/or companion diagnostics. For many drugs, significant benefits can be obtained by combining the drug with a specialized delivery device, when compared to drugs which are primarily delivered by systemic means.

This event will bring together a mix of entrepreneurs, big pharma, and biotech developers to discuss the medical and business challenges where delivery innovations provide a unique solution. Entrepreneurs will discuss strategies for funding and development issues specific to drug delivery products. Speakers from pharma and biotech will discuss challenges across the value chain of manufacturing and selling combination products globally.

CBSET’s Director of Research and Innovation, Dr. Rami Tzafriri, will be one of the presenters, and CBSET will be exhibiting at this event. If you would like to meet up with us there, please contact us.

Related CBSET Services:

Related Publications:


Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings. Tzafriri AR, Garcia-Polite F, Li X, Keating J, Balaguer JM, Zani B, Bailey L, Markham P, Kiorpes TC, Carlyle W, Edelman ER. Journal of Controlled Release. Volume 274, 28 March 2018, Pages 102-108


Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosisAbraham R. Tzafriri, Fernando Garcia-Polite, Brett Zani, James Stanley, Benny Muraj, Jennifer Knutson, Robert Kohler, Peter Markham, Alexander Nikanorov, Elazer R. Edelman. Journal of Controlled Release, Volume 264, 28 October 2017, Pages 203-210.


A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials: A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044.